WO2018097527A1 - Composition pour le blanchiment de la peau ou le traitement des plaies, contenant un plasma liquide - Google Patents

Composition pour le blanchiment de la peau ou le traitement des plaies, contenant un plasma liquide Download PDF

Info

Publication number
WO2018097527A1
WO2018097527A1 PCT/KR2017/012771 KR2017012771W WO2018097527A1 WO 2018097527 A1 WO2018097527 A1 WO 2018097527A1 KR 2017012771 W KR2017012771 W KR 2017012771W WO 2018097527 A1 WO2018097527 A1 WO 2018097527A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
growth factor
skin
liquid plasma
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/012771
Other languages
English (en)
Korean (ko)
Inventor
김철호
강성운
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajou University Industry Academic Cooperation Foundation
Original Assignee
Ajou University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170110761A external-priority patent/KR102006784B1/ko
Priority claimed from KR1020170110760A external-priority patent/KR101979105B1/ko
Application filed by Ajou University Industry Academic Cooperation Foundation filed Critical Ajou University Industry Academic Cooperation Foundation
Priority to US16/464,180 priority Critical patent/US11759407B2/en
Publication of WO2018097527A1 publication Critical patent/WO2018097527A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a composition for skin whitening or wound healing comprising liquid plasma. More specifically, the present invention relates to a cosmetic composition for skin whitening containing a liquid plasma as an active ingredient, and a pharmaceutical composition for treating or preventing skin pigmentation diseases.
  • the present invention comprises a pharmaceutical composition for treating wounds, a quasi-drug composition, nutraceutical composition, and administering the composition to the subject or applying to the skin of the subject comprising a liquid plasma and growth factors as an active ingredient. It relates to a wound treatment method.
  • the composition comprising the liquid plasma and the growth factor of the present invention is excellent in wound healing effect by inducing proliferation of fibroblasts, and may be usefully applied to medicines including skin external preparations for wound treatment.
  • Melanogenesis is a defense mechanism against melanocyte melanocytes (melanocytes) that stimulate the production of melanin, which increases melanogenesis, which is transferred to keratinocytes and accumulated in the skin epidermis.
  • melanin protects the skin
  • hyperpigmentation of the skin causes blemishes, freckles, darkening of the skin after skin inflammation, and senile pigment spots. It may also result.
  • the melanin production process is made by tyrosinase, an amino acid called tyrosinase, which is transformed into dopa and dopaquinone, followed by a non-enzymatic oxidation reaction. It is known that spots, blotch, etc. are produced.
  • Korean Patent Publication No. 2005-0509848 discloses a whitening cosmetic containing a keratone derivative isolated from the previous issue.
  • Korean Patent Publication No. 2005-0479741 discloses a whitening cosmetic containing a glucose acylated derivative.
  • hydroquinone is once recognized for its effects, but its use is generally limited because of its sensitivity.
  • Ascorbic acid is easily oxidized, and the cosmetics blended with it cause discoloration and deodorization.
  • the substances derived from plant extracts have a great difference in efficacy depending on the origin of the plant, making it difficult to maintain homogeneity of the product. The disadvantage is that the synthesis efficiency is very low.
  • Skin acts as a protective barrier to the body and is the body's primary line of defense against disease, and the epidermis provides a barrier to microbial invasion.
  • Wound healing is a complex process that generally involves three stages: inflammation, proliferation, and remodeling. The first step involves clotting to achieve haemostasis, and supplementation of neutrophils to destroy bacteria and necrotic tissue, followed by supplementation of macrophages. During the second stage, angiogenesis occurs, where endothelial cells enter the wound site, while fibroblasts enter the wound site and help to produce granulation tissue.
  • Wound closure refers to the complete closure of the skin clinically, keratinocyte (fibroblast), fibroblast (endothelial cell), macrophage (macrophage), platelet (platelet) It is a complex process in which different kinds of cells interact and regulate. Each process is regulated by a complex signaling network regulated by many growth factors, cytokines and chemokines.
  • Wounds need to be treated quickly to reduce the risk of secondary infection.
  • the inflammatory response persists during wound healing, normal wound healing is delayed because the progression from the inflammatory phase to the proliferative phase is not made. For this reason, the development of wound treatment methods that do not induce an inflammatory response is actively progressing.
  • the present invention relates to a skin whitening or wound healing composition comprising a liquid plasma, and the present inventors have made diligent efforts to develop a method for the fundamental treatment of pigmentation of the skin.
  • the liquid plasma inhibits tyrosinase activity and melanin biosynthesis. It has been confirmed that it can be used for skin whitening because it shows an inhibitory effect, and the present inventors have made diligent efforts to develop a method for the fundamental treatment of wounds, and as a result, liquid plasma and epidermal growth factor (fibroblast) in fibroblasts ( Epidermal growth factor (EGF) was confirmed that the regeneration of fibroblasts was promoted to complete the present invention.
  • fibroblast epidermal growth factor
  • EGF epidermal growth factor
  • the present invention has been made to solve the problems of the prior art, and relates to a composition for skin whitening or wound treatment comprising a liquid plasma.
  • One object of the present invention is to provide a composition for skin whitening that exhibits excellent whitening effect through tyrosinase activity inhibitory effect and melanin biosynthesis inhibitory effect, and also excellent liquidity in terms of stability.
  • Another object of the present invention to provide a cosmetic composition for skin whitening containing the composition for skin whitening comprising the liquid plasma.
  • Another object of the present invention to provide a pharmaceutical composition for the treatment or prevention of pigmentation diseases containing a composition for skin whitening comprising the plasma.
  • Another object of the present invention is to provide a pharmaceutical composition for wound treatment comprising liquid plasma and growth factors as an active ingredient.
  • Another object of the present invention to provide a quasi-drug composition for wound treatment comprising a liquid plasma and growth factors as an active ingredient.
  • Another object of the present invention to provide a health care food composition for wound treatment comprising a liquid plasma and growth factors as an active ingredient.
  • Yet another object of the present invention is to provide a wound healing method comprising administering to a subject a composition comprising a liquid plasma and a growth factor as an active ingredient.
  • Yet another object of the present invention is to provide a wound healing method comprising applying to the skin of an individual a composition comprising a liquid plasma and a growth factor as an active ingredient.
  • non thermal plasma treated solution refers to the generation of high density high energy plasma in a liquid, which can be prepared by exposure to atmospheric nonthermal plasma (NTP) at atmospheric pressure.
  • NPS nonthermal plasma
  • liquid plasma may be used interchangeably with the term “plasma-conditioned liquid material” and the term “liquid material” may be used without limitation in the form of a liquid, but preferably Preferably water, saline, buffer, or medium, most preferably medium.
  • culture media refers to a medium capable of supporting cell growth and survival in vitro , and refers to a conventional medium used in the art appropriate for the culture of cells. It includes everything. Depending on the type of cells, medium and culture conditions can be selected.
  • the basal medium used for culturing the cells is preferably a cell culture minimum medium (CCMM), and generally includes a carbon source, a nitrogen source and a trace element component.
  • CCMM cell culture minimum medium
  • Such cell culture basal media include, for example, Dulbeco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basic Medium Eagle (BME), RPMI1640, F-10, F-12, (Minimal Essential Medium), GMEM ( Glasgow's Minimal Essential Medium), Iscove's Modified Dulbecco's Medium, but are not limited to these.
  • whitening refers to the ability of the skin to be continuously exposed to ultraviolet light to increase melanocytes and thereby prevent excessive deposition of melanin pigment on the skin, or to thin the previously deposited melanin pigment. . As a result, it is possible to suppress the production of blemishes and freckles caused by excessive deposition of melanin pigment.
  • growth factor refers to a polypeptide that promotes the division, growth and differentiation of several cells, and refers to epidermal growth factor (EGF), platelet derived growth factor-AA (PDGF-AA), insulin-like growth Factor-1 (IGF-1), transforming growth factor- ⁇ (TGF- ⁇ ) or fibroblast growth factor (FGF), but is not limited thereto.
  • EGF epidermal growth factor
  • PDGF-AA platelet derived growth factor-AA
  • IGF-1 insulin-like growth Factor-1
  • TGF- ⁇ transforming growth factor- ⁇
  • FGF fibroblast growth factor
  • treatment means any action that improves or beneficially alters skin pigmentation, wounds, and other symptoms thereof by using liquid plasma according to the present invention.
  • Those skilled in the art will be able to determine the exact criteria for skin pigmentation, and determine the degree of improvement, improvement and treatment, with reference to data provided by the Korean Medical Association.
  • prevention means any action that inhibits or delays skin pigmentation, wounds, and other symptoms caused by using the liquid plasma according to the present invention. It will be apparent to those skilled in the art that the compositions herein having a therapeutic effect on skin pigmentation diseases or wounds can be prevented using the liquid plasma according to the invention before the initial symptoms or symptoms of skin pigmentation or wounds appear.
  • the term "pharmaceutical composition” means a composition to be administered for a specific purpose.
  • the pharmaceutical composition of the present invention includes a liquid plasma prepared by irradiating a plasma to a liquid substance as an active ingredient, and may include a protein and a pharmaceutically acceptable carrier, excipient or diluent involved therein.
  • Said "pharmaceutically acceptable" carrier or excipient means that which has been approved by the governmental regulatory authority, or listed in government or other generally approved pharmacopoeia for use in vertebrates, and more particularly in humans. do.
  • the pharmaceutical compositions of the invention may be in the form of suspensions, solutions or emulsions in oily or aqueous carriers, and may be prepared in the form of solids or semisolids.
  • the pharmaceutical compositions of the present invention may include formulating agents such as suspending, stabilizing, dissolving and / or dispersing agents and may be sterilized.
  • the pharmaceutical composition may be stable under the conditions of manufacture and storage, and may be preserved against the contaminating action of microorganisms such as bacteria or fungi.
  • the pharmaceutical compositions of the present invention may be in sterile powder form for reconstitution with a suitable carrier prior to use.
  • the pharmaceutical compositions may be in unit-dose form, in microneedle patches, in ampoules, or in other unit-dose containers, or in multi-dose containers.
  • the pharmaceutical composition may be stored in a freeze-dried (freeze-dried) state, which requires the addition of a sterile liquid carrier, eg, water for injection just before use.
  • a sterile liquid carrier eg, water for injection just before use.
  • Immediately injectable solutions and suspensions may be prepared as sterile powders, granules or tablets.
  • the pharmaceutical compositions of the present invention can be formulated or included in the form of microspheres in a liquid.
  • the pharmaceutical compositions of the present invention may comprise their pharmaceutically acceptable compounds and / or mixtures at concentrations between 0.001 and 100,000 U / kg.
  • the pharmaceutical compositions of the present invention may include suitable excipients, preservatives, suspending agents, additional stabilizers, dyes, buffers, antibacterial agents, antifungal agents, and isotonic agents, for example, sugars or sodium chloride.
  • suitable excipients such as used herein, the term "stabilizer” refers to a compound that is optionally used in the pharmaceutical compositions of the present invention to increase shelf life.
  • the stabilizer can be a sugar, an amino acid, or a polymer.
  • the pharmaceutical composition of the present invention may include one or more pharmaceutically acceptable carriers, and the carrier may be a solvent or a dispersion medium.
  • pharmaceutically acceptable carriers include water, saline, ethanol, polyols (eg glycerol, propylene glycol and liquid polyethylene glycols), oils, and suitable mixtures thereof.
  • sterilization techniques applied to the pharmaceutical compositions of the present invention include filtration through bacteria-inhibiting filters, terminal sterilization, incorporation of sterile preparations, irradiation, sterile gas irradiation, heating, vacuum drying and freeze drying. do.
  • administration means introducing the composition of the present invention to a patient in any suitable manner, and the route of administration of the composition of the present invention may be administered via any general route as long as it can reach the desired tissue.
  • the method of treatment of the present invention may comprise administering the pharmaceutical composition in a pharmaceutically effective amount.
  • the effective amount is defined as the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type and formulation of the patient and the age, body weight, general health condition, sex and diet, time of administration, route of administration And various factors, including the rate of secretion of the composition, the duration of treatment, and the drugs used concurrently.
  • the "cosmetic composition” is a composition for improving or improving skin pigmentation, wound, and other symptoms caused thereby.
  • Cosmetic composition comprising the composition of the present invention as an active ingredient, lotion, nutrition lotion, nutrition essence, massage cream, beauty bath additives, body lotion, body milk, bath oil, baby oil, baby powder, shower gel, shower cream, sun Screen lotion, sunscreen cream, suntan cream, skin lotion, skin cream, sunscreen cosmetic, cleansing milk, depilatory (cosmetic), face and body lotion, face and body cream, skin whitening cream, hand lotion, hair lotion, Cosmetic Cream, Jasmine Oil, Bath Soap, Water Soap, Beauty Soap, Shampoo, Hand Cleanser (Hand Cleaner), Medicated Soap (Non-Medical), Cream Soap, Facial Wash, Hair Rinse, Makeup Soap, Tooth Whitening Gel, Toothpaste, etc.
  • composition of the present invention may further comprise a suitable carrier, excipient or diluent commonly used in the preparation of cosmetic compositions.
  • Carriers, excipients or diluents that may be further added to the cosmetic compositions of the present invention include purified water, oils, waxes, fatty acids, fatty acid alcohols, fatty acid esters, surfactants, humectants, thickeners, antioxidants, viscosity stabilizers, kills Rating agents, buffers, lower alcohols, and the like.
  • a whitening agent, a moisturizing agent, vitamins, sunscreens, perfumes, dyes, antibiotics, antibacterial agents, antifungal agents may be included as necessary.
  • the oil may be hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil, avocado oil, wax, wax, carnauba, candelilla, montan, ceresin, liquid paraffin, lanolin Can be used.
  • Stearic acid, linoleic acid, linolenic acid, oleic acid may be used as the fatty acid, and cetyl alcohol, octyldodecanol, oleyl alcohol, pantenol, lanolin alcohol, stearyl alcohol, hexadecanol may be used as fatty acid alcohol.
  • isopropyl myristate, isopropyl palmitate, butyl stearate may be used as the fatty acid ester.
  • surfactants cationic surfactants, anionic surfactants and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferred as much as possible.
  • it may include a hygroscopic agent, a thickener, an antioxidant, and the like, which are widely known in the cosmetic field, and their types and amounts are known in the art.
  • step (a) filling the plasma generating apparatus with a carrier gas; (b) generating a plasma by supplying a voltage of 0.5 kV to 20 kV and a frequency of 10 to 30 kHz to the plasma generator; And (c) irradiating the generated plasma to a liquid material, wherein the carrier gas in step (a) is selected from the group consisting of nitrogen, helium, argon, and oxygen. It provides a method for producing a liquid plasma, characterized in that any one or more selected, the liquid material in the step (c) provides a method for producing a liquid plasma which is water, saline, buffer, or medium.
  • liquid plasma composition comprising a liquid plasma prepared by any one or more of the above methods.
  • a pharmaceutical composition for the prevention or treatment of skin pigmentation disease comprising the liquid plasma composition as an active ingredient, wherein the skin pigmentation disease is spots, freckles, black spots, birthmarks, It provides a pharmaceutical composition for the prevention or treatment of skin pigmentation disease, characterized in that any one or more selected from the group consisting of pigmentation by drugs, pigmentation after inflammation, and hyperpigmentation occurring in dermatitis.
  • a method for preventing or treating skin pigmentation disease comprising administering the pharmaceutical composition to an individual, wherein the skin pigmentation disease is a blemish, freckles, black spots, birthmarks, It provides a method for preventing or treating skin pigmentation disease, characterized in that any one or more selected from the group consisting of pigmentation by drugs, pigmentation after inflammation, and hyperpigmentation occurring in dermatitis.
  • a cosmetic composition for skin whitening comprising the liquid plasma composition as an active ingredient.
  • the pharmaceutical composition provides a pharmaceutical composition for wound treatment further comprising a growth factor
  • the growth Factors include epidermal growth factor (EGF), platelet derived growth factor-AA (PDGF-AA), insulin-like growth factor-1 (IGF-1), transforming growth factor- ⁇ (TGF- ⁇ ) or fibroblast growth factor
  • EGF epidermal growth factor
  • PDGF-AA platelet derived growth factor-AA
  • IGF-1 insulin-like growth factor-1
  • TGF- ⁇ transforming growth factor- ⁇
  • FGF fibroblast growth factor
  • a wound treatment method comprising administering the pharmaceutical composition to a subject, wherein the wound is a wound that is skin damage caused by cuts, peels, rashes, inflammations, ulcers, or scratches.
  • the wound is a wound that is skin damage caused by cuts, peels, rashes, inflammations, ulcers, or scratches.
  • the composition provides a quasi-drug composition for wound treatment further comprising a growth factor, the growth factor Epidermal growth factor (EGF), platelet derived growth factor-AA (PDGF-AA), insulin-like growth factor-1 (IGF-1), transforming growth factor- ⁇ (TGF- ⁇ ) or fibroblast growth factor ( FGF) provides a quasi-drug composition for wound treatment.
  • EGF Epidermal growth factor
  • PDGF-AA platelet derived growth factor-AA
  • IGF-1 insulin-like growth factor-1
  • TGF- ⁇ transforming growth factor- ⁇
  • FGF fibroblast growth factor
  • Cosmetic composition for skin whitening comprising a liquid plasma according to the present invention
  • the composition for the treatment or prevention of pigmentation diseases shows an excellent inhibitory effect on tyrosinase activity and melanin biosynthesis
  • whitening cosmetic composition skin pigmentation
  • the composition comprising a liquid plasma and a growth factor according to the present invention can promote the regeneration of fibroblasts. Therefore, it is expected that the composition comprising the liquid plasma and the growth factor according to the present invention can promote the healing of wounds.
  • FIG. 1A and 1B illustrate a method of manufacturing a liquid plasma (NTS) according to the present invention.
  • Figure 2 shows the pigment formation inhibitory effect of the liquid plasma according to the present invention in Zebrafish.
  • Figure 3 shows the pigmentation inhibitory effect in the human tissue skin of the liquid plasma according to the present invention.
  • 4a and 4b show the effect of inhibiting tyrosinase activity in the human tissue skin of liquid plasma according to the present invention.
  • Figure 5 shows the results of the toxicity effect in the Melanocyte of the liquid plasma according to the present invention.
  • 6a and 6b show the effect of reducing the Melanogenesis marker in the human melanocyte of the liquid plasma according to the present invention.
  • Figure 7 shows the wound healing effect of the liquid plasma according to the present invention.
  • Figure 8 shows the cytotoxicity effect of the liquid plasma according to the present invention.
  • Human foreskin tissue was cultured in Transwell (DMEM high glucose + 4% FBS), and the liquid plasma was treated with 1min / 1ml. After incubation for 3 days, the fixation was observed through Fontana-masson staining. As a result, it was confirmed that the epidermal stain was lighter than that of the control group in the liquid plasma treated Human Tissue skin.
  • Example 1-2 Liquid plasma ( NTS ) And the growth factor comprising the growth factor
  • Example 2-1 Zebrafish Pigmentation inhibitory effect
  • the fertilized eggs collected from zebrafish male and female were put into zebrafish fertilized egg culture medium (Egg water, 0.2 g sea slat / L) and generated for 24 hours, and then the liquid plasma prepared in Example 1 was treated.
  • the fertilized egg corion was punched out with tweezers, and the fertilized egg showing the toxicity of the sample was removed after 24 hours. After complete removal, the samples of the same concentration were processed again. After 48 hours of sample treatment, the degree of pigmentation of the sample treated group compared to the control group was observed by a stereo microscope and confirmed, and the results are shown in FIG. 2.
  • zebra fish treated with liquid plasma were found to inhibit the formation of pigments compared to the control.
  • Example 2-2 Inhibitory Effect of Pigmentation on Human Tissue Skin
  • Example 1 After incubating human foreskin tissue in Transwell (DMEM high glucose + 4% FBS), the liquid plasma prepared in Example 1 was treated with 1min / 1ml. After culturing for 3 days and fixed, the degree of pigment formation was observed through Fontana-masson stain, and the results are shown in FIG. 3.
  • epidermal staining was lighter than that of the control group in the human plasma tissue treated with liquid plasma.
  • the human foreskin sample was seeded with 2 ⁇ 10 6 in a 60 mm dish, and then treated with 1 min / 1 ml of the liquid plasma prepared in Example 1. After 24 hours of incubation and fixation, Western blot, PCR, tyrosinase activity and melanin content were measured, and the results are shown in FIGS. 4A and 4B.
  • Example 2-4 In melanocyte Toxic effect verification
  • Example 5 After treating the liquid plasma prepared in Example 1 to the human melanocyte, the cytotoxicity was confirmed by time, and the results are shown in FIG. 5.
  • liquid plasma according to the present invention does not exhibit toxicity in human melanocyte.
  • Example 2-5 Human in melanocyte Melanogenesis marker reduction effect
  • liquid plasma according to the present invention was confirmed to reduce melanogenesis markers in human melanocyte, which was confirmed to reduce the RNA level of Tyrosinase as well as protein level.
  • Example 3-1 Check the effect of wound healing
  • the wound treatment effect did not appear in the group treated with liquid plasma alone, but the wound treatment effect was confirmed in the group treated with EGF alone.
  • the wound treatment effect was confirmed in the group treated with EGF alone.
  • a significant wound healing effect was observed than when treated with EGF alone.
  • composition according to the present invention was confirmed that there is no fibroblast cytotoxicity.
  • composition containing the liquid plasma as an active ingredient is excellent in the skin whitening and skin pigmentation disease treatment or prevention effect.
  • composition comprising the liquid plasma and growth factors of the present invention is excellent in wound healing by inducing proliferation of fibroblasts, and may be usefully applied to medicines including skin external preparations for wound treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pour le blanchiment de la peau ou le traitement des plaies, contenant un plasma liquide. Plus particulièrement, la présente invention concerne une composition cosmétique pour le blanchiment de la peau et une composition pharmaceutique pour le traitement prophylactique ou thérapeutique de troubles de pigmentation de la peau, les deux contenant du plasma liquide en tant que principe actif. De plus, la présente invention concerne : une composition pharmaceutique, une composition de quasi-médicament, et une composition d'alicament fonctionnel, toutes étant destinées au traitement des plaies et contenant, en tant que principes actifs, du plasma liquide et des facteurs de croissance ; et un procédé de traitement des plaies comprenant une étape d'administration des compositions à un sujet ou d'application des compositions à la peau du sujet. La composition selon la présente invention contenant du plasma liquide et des facteurs de croissance induit la prolifération des fibroblastes de manière à présenter un excellent effet de traitement des plaies, ce qui est utile dans l'application à des produits pharmaceutiques, y compris une préparation cutanée à usage externe pour le traitement des plaies, et analogues.
PCT/KR2017/012771 2016-11-25 2017-11-13 Composition pour le blanchiment de la peau ou le traitement des plaies, contenant un plasma liquide Ceased WO2018097527A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/464,180 US11759407B2 (en) 2016-11-25 2017-11-13 Composition for skin whitening or wound treatment, containing liquid plasma

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2016-0158678 2016-11-25
KR10-2016-0158673 2016-11-25
KR20160158678 2016-11-25
KR20160158673 2016-11-25
KR10-2017-0110760 2017-08-31
KR1020170110761A KR102006784B1 (ko) 2016-11-25 2017-08-31 액상 플라즈마를 포함하는 상처 치료용 조성물
KR1020170110760A KR101979105B1 (ko) 2016-11-25 2017-08-31 액상 플라즈마를 포함하는 피부 미백용 조성물
KR10-2017-0110761 2017-08-31

Publications (1)

Publication Number Publication Date
WO2018097527A1 true WO2018097527A1 (fr) 2018-05-31

Family

ID=62195592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012771 Ceased WO2018097527A1 (fr) 2016-11-25 2017-11-13 Composition pour le blanchiment de la peau ou le traitement des plaies, contenant un plasma liquide

Country Status (1)

Country Link
WO (1) WO2018097527A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
JP2014212839A (ja) * 2013-04-23 2014-11-17 沖野　晃俊 大気圧プラズマを用いた生物細胞および外皮系のケア方法および大気圧プラズマを用いた生物細胞および外皮系のケア装置
WO2015191843A1 (fr) * 2014-06-13 2015-12-17 Advanced Plasma Therapies, Inc. Méthodes vétérinaires d'utilisation d'oxyde nitrique dans un état plasmique pour le traitement de troubles médicaux et de maladies chez l'animal
KR101635718B1 (ko) * 2016-01-29 2016-07-01 김민기 플라즈마를 이용한 이미용장치
KR101657063B1 (ko) * 2015-04-09 2016-09-13 아주대학교산학협력단 암 예방 또는 치료용 액상 플라즈마

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
JP2014212839A (ja) * 2013-04-23 2014-11-17 沖野　晃俊 大気圧プラズマを用いた生物細胞および外皮系のケア方法および大気圧プラズマを用いた生物細胞および外皮系のケア装置
WO2015191843A1 (fr) * 2014-06-13 2015-12-17 Advanced Plasma Therapies, Inc. Méthodes vétérinaires d'utilisation d'oxyde nitrique dans un état plasmique pour le traitement de troubles médicaux et de maladies chez l'animal
KR101657063B1 (ko) * 2015-04-09 2016-09-13 아주대학교산학협력단 암 예방 또는 치료용 액상 플라즈마
KR101635718B1 (ko) * 2016-01-29 2016-07-01 김민기 플라즈마를 이용한 이미용장치

Similar Documents

Publication Publication Date Title
WO2021107706A1 (fr) Nouvelle utilisation d'exosomes du lait
WO2016167527A1 (fr) Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci
WO2017010597A1 (fr) Composition cosmétique pour le soin des cheveux contenant un facteur de croissance destiné à favoriser la régénération et la croissance des cellules folliculaires, un variant de facteur de croissance des fibroblastes de stabilité élevée, et un peptide de noggine
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
WO2017146514A1 (fr) Composition cosmétique de soin capillaire contenant un mutant de facteur de croissance des fibroblastes 9 hautement stable en tant que substance active
WO2022177217A2 (fr) Composition pour la régénération, le blanchiment, l'antioxydation de la peau, ou le traitement des plaies, comprenant un exosome dérivé de cellules souches utilisé en tant que principe actif, et utilisation associée
KR102158675B1 (ko) 인간 유도만능줄기세포 유래 엑소좀을 포함하는 피부 재생 및 노화 개선용 조성물
WO2023055007A1 (fr) Peptide possédant une activité anti-vieillissement, et son utilisation
WO2023054817A1 (fr) Peptide ayant une activité anti-âge et son utilisation
WO2018004300A1 (fr) Dispositif de production de plasma et procédé permettant de traiter la chute des cheveux à l'aide dudit dispositif de production de plasma
WO2017135556A1 (fr) Composition contenant du gdf11 et son utilisation
WO2017175909A1 (fr) Composition pharmaceutique pour la cicatrisation des plaies contenant de la substance p
WO2018186505A1 (fr) Composition destinée au traitement des cicatrices, à l'amélioration de la peau, et à la prévention ou au traitement de la perte de cheveux comprenant un exosome dérivé de cellules souches, et son procédé de préparation
WO2017200288A1 (fr) Composition pour le blanchiment de la peau, la prévention du vieillissement de la peau ou l'amélioration des rides de la peau, comprenant un extrait médicinal oriental naturel en tant que substance active
US11759407B2 (en) Composition for skin whitening or wound treatment, containing liquid plasma
WO2023055010A1 (fr) Peptide ayant une activité anti-âge et son utilisation
WO2023022414A1 (fr) Nouvelle composition comprenant un exosome dérivé d'iris en tant que principe actif
WO2019132217A1 (fr) Composition cosmétique comprenant comme principe actif une solution fermentée du fruit de styphnolobium japonicum ou un extrait liquide de celle-ci et destinée à réduire les rides de la peau, et procédé de préparation associé
WO2025143444A1 (fr) Composition comprenant un exosome dérivé de camellia japonica callus en tant que principe actif pour améliorer l'état de la peau
WO2021162206A1 (fr) Composition pour la prévention ou le traitement de la perte de cheveux comprenant un milieu de culture de tissu de follicules pileux
WO2018097527A1 (fr) Composition pour le blanchiment de la peau ou le traitement des plaies, contenant un plasma liquide
WO2019139403A1 (fr) Composition contenant de la séricine, un extrait de torilis japonica et un extrait de viscum album pour la régénération de la peau, l'apaisement de la peau ou la cicatrisation des plaies
KR101979105B1 (ko) 액상 플라즈마를 포함하는 피부 미백용 조성물
WO2024228415A1 (fr) Composition pour prévenir ou traiter la chute des cheveux, ou pour favoriser la pousse des cheveux ou la nutrition des cheveux, comprenant, en tant que principe actif, une matrice extracellulaire décellularisée dérivée de kératinocytes cutanés
WO2022265150A1 (fr) Milieu de culture riche en exosomes de cellules souches immortalisées et composition fonctionnelle comprenant de la toxine botulique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17874297

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17874297

Country of ref document: EP

Kind code of ref document: A1